Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials
The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To report the incidence of pancreatitis in type 2 diabetes trials of liraglutide and details of all pancreatitis cases. RESEARCH DESIGN AND METHODS: Data from Novo Nordisk–sponsored trials with liraglutide (phase 2 and 3; NN2211 identifiers) completed by 19 April 2013 were pooled. All pancreatitis cases were reviewed. RESULTS: Total exposure to liraglutide and active comparators was 5,021 and 1,354 patient-years, respectively (n = 6,345 and 1,846, respectively). Eight cases of acute pancreatitis (AP) with liraglutide and one with any comparator (glimepiride) were found. The incidence of AP was 1.6 cases/1,000 patient-years exposure (PYE) for liraglutide vs. 0.7 cases/1,000 PYE for total active comparators. One of the eight AP cases reported with liraglutide did not meet diagnostic criteria for AP. In six of these eight cases, recognized risk factors for AP were present and/or the onset of AP occurred >6 months after liraglutide initiation. All patients were receiving multiple medications. Four cases of chronic pancreatitis (CP) with liraglutide and none with comparators were found. One of these four cases fulfilled diagnostic criteria for CP; these criteria were not met or information was missing in the remaining three. CONCLUSIONS: Based on the small number of cases observed, the incidences of reported AP and CP were numerically greater with liraglutide than with comparators. Not all cases fulfilled diagnostic criteria, and confounding variables were present in 75% of the AP cases with liraglutide therapy, precluding firm conclusions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Higher levels of lipase and amylase were observed in the liraglutide group, a finding that is similar to results in other studies.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [24]
In the citing paper
“There has been considerable interest in a potential association between the use of GLP-1–receptor agonists and pancreatitis and pancreatic cancer, although there is no consistent preclinical, pharmacovigilance, or epidemiologic evidence to date.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [24]
In the citing paper
“However, some rare cases of acute pancreatitis and neoplasms have been reported [53–55]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [53]
In the citing paper
“In addition, GLP-1RAs use may be associated with an increased risk of acute pancreatitis and thyroid cancer, and the FDA has warned the public about these AEs (10–12).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [10]
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“50) compared with placebo, with a numerical imbalance between arms (47,48).”
BackgroundPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Drug-Induced Acute Pancreatitis: An Evidence-Based Review
Badalov, N., Baradarian, R., Iswara, K., Li, J., Steinberg, W., & Tenner, S. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.11.023 · Cited by 589 · cited 1×
“There is a substantial body of literature on drug-induced acute pancreatitis (40).”
BackgroundSelf-citationPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435
Research works printed but not linked: 1
- Gourdy, 2013, Effectiveness and persistence with liraglutide among patients with type 2 diabetes. One year data from EVIDENCE: a 2-year, prospective, follow up, post-marketing study (Abstract), Diabetologia, 56, S369
Cited by
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
“However, some rare cases of acute pancreatitis and neoplasms have been reported [53–55]; thus the establishment of safety of GLP-1-based therapy should be validated by sufficient further studies.”
BackgroundNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Although few cases of pancreatitis were reported in clinical trials with liraglutide, the incidence among patients receiving liraglutide was greater than those among patients receiving placebo or comparator medications [73].”
ResultMonami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
“FIGURE 2 MH-OR with 95% CI for pancreatitis for GLP-1 receptor agonists vs placebo or other active comparators Study name Statistics for each study MH odds ratio and 95% CI Relative MH odds Lower Upper weight 0,16Seino 2010 ratio 0,63 0,16Zinman 2009 0,63 Diamant 2012 0,32 0,63 NCT00976937 0,34 0,63 0,36Grunberger 201…”
InfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1611289 · Cited by 195
Semaglutide for type 2 diabetes mellitus: A systematic review and meta‐analysis
Andreadis, P., Karagiannis, T., Malandris, K., Avgerinos, I., Liakos, A., Manolopoulos, A., Bekiari, E., Matthews, D. R., & Tsapas, A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13361 · Cited by 153
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
Cahn, A., & Cefalu, W. T. (2016) · Diabetes Care · doi:10.2337/dcs15-3007 · Cited by 118
Dungan, K. M., Weitgasser, R., Perez Manghi, F., Pintilei, E., Fahrbach, J. L., Jiang, H. H., Shell, J., & Robertson, K. E. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12634 · Cited by 99
“Consistent with the class, measurable increases in pancreatic enzymes were observed, but there were no adjudicated cases of pancreatitis and no cases of pancreatic carcinoma [18,27,29,30].”
Liraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
“Although, as stated by the authors, the incidences of pancreatitis were numerically greater in the liraglutide arm than with comparators, not all cases fulfilled the diagnostic criteria, and confounding variables were present in 75% of the cases of acute pancreatitis with liraglutide therapy [99].”
BackgroundSteinberg, W. M., Rosenstock, J., Wadden, T. A., Donsmark, M., Jensen, C. B., & DeVries, J. H. (2017) · Diabetes Care · doi:10.2337/dc16-2684 · Cited by 76
“However, although the totality of reviewed data provides reassurance, pancreatitis continues to be considered a risk until more data become available (4,5).”
Self-citationKalra, S., Das, A. K., Sahay, R. K., Baruah, M. P., TIWASKAR, M. H., Das, S., Chatterjee, S., Saboo, B., Bantwal, G., Bhattacharya, S., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0669-4 · Cited by 70
Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
Seo, Y.-G. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20059 · Cited by 57
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 57
Patoulias, D., Doumas, M. N., Kotsis, V., Stavropoulos, K., Imprialos, K. P., Zografou, I., Petidis, K., Bakatselos, S., & Karagiannis, A. I. (2020) · Current Diabetes Reviews · doi:10.2174/1573399815666190614141918 · Cited by 53
Liu, Y., Zhang, X., Chai, S., Zhao, X., & Ji, L. (2019) · Journal of Diabetes Research · doi:10.1155/2019/1534365 · Cited by 47
Gautier, J.-F., Martinez, L., Penfornis, A., Eschwège, E., Charpentier, G., Huret, B., Madani, S., & Gourdy, P. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0245-x · Cited by 40
“6 cases per 1000 patient-years reported in a recent meta-analysis of 18 clinical trials involving liraglutide [33], and is less than the background incidence (4.”
BackgroundInsulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
Gough, S. C. L., Jain, R., & Woo, V. C. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1113129 · Cited by 40
“A post hoc analysis of pooled patient-level data from the liraglutide clinical development program reported eight cases of acute pancreatitis with liraglutide (n = 6345) compared with one case with comparators (n = 1846).[25] The incidence of acute pancreatitis was 1.”
MethodNauck, M. A., Frossard, J.-L., Barkin, J. S., Anglin, G., Hensley, I. E., Harper, K. D., & Milicevic, Z. (2017) · Diabetes Care · doi:10.2337/dc16-0984 · Cited by 36
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 35
“Overall, human studies have so far not revealed conclusive results as to the pancreatitis risk after incretin therapies, mainly due to numerous confounding factors [117].”
ResultFan, M., Jiang, H., Zhang, Y., Ma, Y., Li, L., & Wu, J. (2018) · Medical Science Monitor · doi:10.12659/msm.906286 · Cited by 32
Cystic Fibrosis-Related Diabetes: Clinical approach and knowledge gaps
Prentice, B. J., Potter, K. J., Coriati, A., Boudreau, V., Rusnell, L., Kherani, T., Senior, P. A., Hameed, S., & RABASA-LHORET, R. P. R. (2022) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2022.10.001 · Cited by 29
Incretin-Based Drugs and Adverse Pancreatic Events: Almost a Decade Later and Uncertainty Remains
Azoulay, L. (2015) · Diabetes Care · doi:10.2337/dc15-0347 · Cited by 27
Acute pancreatitis during GLP-1 receptor agonist treatment. A case report
Chis, B. A., & Fodor, D. (2018) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-804 · Cited by 26
Aronen, A., Guilabert, L., Hadi, A., Kiudelis, V., Panaitescu, A., Włodarczyk, B., Laukkarinen, J., Regnér, S., & de‐Madaria, E. (2024) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-23-125 · Cited by 19
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 19
Liraglutide-Induced Pancreatitis: A Case Report and Literature Review
Javed, H., Jagirdhar, G. S. K., Kashyap, R., & Vekaria, P. (2023) · Cureus · doi:10.7759/cureus.38263 · Cited by 17
“Literature on the observation of post-marketing effects and pre-marketing reports of liraglutide-related pancreatitis, as well as the incidence of symptoms after the initiation of liraglutide, is highly suggestive of a relationship [5, 7].”
BackgroundLiraglutide in Weight Management.
Pi‐Sunyer, X. (2015) · PubMed · doi:10.1056/nejmc1509759 · Cited by 15
Wangnoo, S. K., Kumar, S., Bhattacharyya, A., Tripathi, S., Akhtar, S., Shetty, R., & Ghosal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.189232 · Cited by 8
Smoke or Fire? Acute Pancreatitis and the Liraglutide Trials
Gale, E. A. (2015) · Diabetes Care · doi:10.2337/dc15-0346 · Cited by 7
“(7) also note the long latency between exposure to liraglutide (196–668 days) and an event of acute pancreatitis in six patients receiving”
BackgroundSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Diamant, M., den Bos, I. C. P.-V., van Raalte, D. H., & Cahen, D. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12612 · Cited by 7
“For instance, six out of seven pancreatitis cases in liraglutide users occurred after >6 months of treatment [34]; thus, to establish pancreatic safety, more mechanistic data are of importance to investigate a causal link, while larger clinical trials are ongoing to establish long-term safety [35].”
BackgroundVetter, M. L., Johnsson, K. M., Hardy, E., Wang, H., & Iqbal, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0627-1 · Cited by 7
First Reported Case of Dulaglutide-Induced Acute Pancreatitis With Normal Serum Lipase Level
Shahbazi, M., Qudsiya, Z., Fahel, A., Amini, A., & Tanoli, T. (2023) · Cureus · doi:10.7759/cureus.40576 · Cited by 5
“88 cases/1,000 patient-years compared to non-incretin therapy) [16,17].”
Svane, M. S., Johannesen, H. H., Martinussen, C., Bojsen-Møller, K. N., Hansen, M. L., Hansen, A. E., Deacon, C. F., Hartmann, B., Keller, S. H., Klausen, T. L., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14106 · Cited by 5
“Initially, there was fear that the rises were signs of pancreatitis.(9) However, an association between the use of”
BackgroundJimeno, C., Kho, S., Santos, G. K. D. L., Buena-Bobis, N., & Villa, M. L. (2018) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.033.02.02 · Cited by 4
The effect of incretin-based drugs on the riks of acute pancreatitis: a review
Czaplicka, A., & Kaleta, B. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01430-6 · Cited by 4
“…investigated the effect in controlling glycaemia with liraglutide in patients with T2DM showed that the incidence of AP is 1.6 cases per 1,000 patient-years of exposure to liraglutide and this is higher when compared to glimepiride, rosiglitazone, insulin glargine, sitagliptin and exenatide [39].”
InfluentialEmoto, M., Oura, T., Matsui, A., Kazama, H., & Iwamoto, N. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0365 · Cited by 4
Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Sood, A., & Swislocki, A. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0134 · Cited by 4
“105,106 Animal studies have mostly been reassuring, except those in high-fat diet mouse, where minimal-to-moderate exacerbation of background findings such as acinar-cell hyperplasia, atrophy, periductal inflammation, or fibrosis were seen.”
Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?
Murphy, C. F., & le Roux, C. W. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.06 · Cited by 4
Current options in obesity pharmacotherapy for children and adolescents
Jung, H. W. (2024) · Precision and Future Medicine · doi:10.23838/pfm.2024.00093 · Cited by 3
Pancreatic Safety in Studies of The Glucagon-Like Peptide-1 Receptor Agonist Albiglutide
Al‐Kawas, F., Anderson, M. A., Enns, R., Wilson, T. Y. H., JOHNSON, S. L., & Mallory, J. M. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0507 · Cited by 2
Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Paldánius, P. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0179 · Cited by 2
The effects of high protein diets and L-Phenylalanine on energy and glucose homeostasis
Norton, M. (2019) · Spiral (Imperial College London) · doi:10.25560/91789 · Cited by 2
Bessere Aussichten für Patienten mit Typ-2-Diabetes
Ritzel, R. A. (2016) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-016-7701-7
“Es bleibt o«en, wie die Befunde, dass unter GLP-1-basierenden Substanzen leichtgradige, aber messbare Anstiege der Pankreasenzyme au¶raten, erklärt werden sollen [9].”
BackgroundLEADER-Studie: 22 %ige Senkung der kardiovaskulären Mortalität
Vardarli, I., & Özcelik, C. (2016) · Der Kardiologe · doi:10.1007/s12181-016-0089-x
Dietary and Medical Management of Obesity
Wilding, J. P. H., & Lim, J. Z. M. (2022) · doi:10.1093/med/9780198870197.003.0225
Investigating Semaglutide in Adult Patients on Body Weight Compared with Other GLP-1 Drugs
Farrash, S., Aleisa, L., Alhazmi, N. Z., Almatrafi, N., Alharbi, T., Kelantan, S., Alotaibi, L., Hunaydi, W., Alnimari, S., Alqarni, N., et al. (2023) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/j9zsdr5dno
Zhong, Q., Yang, A. L., & Volic, I. N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00999-4
Metadata
- Authors
- Jensen, T. M., Saha, K., & Steinberg, W. M.
- Affiliations
- UK Medical Affairs, Novo Nordisk Ltd., Gatwick, U.K.
- Novo Nordisk (Denmark) (DK)
- George Washington University (US)
- Corresponding author
- Jensen, Troels M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-05-12
- Volume
- 38
- Issue
- 6
- Pages
- 1058-1066
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2098737080
- Cited by
- 48
- References
- 36
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 8 · 2015: 10
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-08-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- liraglutide, pancreatitis, acute pancreatitis, chronic pancreatitis, type 2 diabetes, GLP-1 receptor agonists, drug safety, glimepiride, risk factors, confounding
- MeSH terms
- Liraglutide, Acute Disease, Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Risk Factors, Sulfonylurea Compounds, Randomized Controlled Trials as Topic, Pancreatitis, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.